TVHS

Winona Champions Comprehensive Care and Empowers Girls and Women in Temecula

Retrieved on: 
Wednesday, April 3, 2024
Blockchain, Women, Consumer, Fitness & Nutrition, Social Media, Technology, Search Engine Optimization, Search Engine Marketing, Publishing, Public Relations, Investor Relations, Marketing, Advertising, Health, Communications, Continuing, University, Primary, Secondary, Education, Mother, Organization, LMNT, Temecula Valley High School, Q&A, Sport, Learning, Yoga, Menopause, TVHS, Lululemon Athletica, Athletics, Woman, Meditation, HIIT, Multimedia, Medical director, Nursing

Winona , a leading advocate for comprehensive wellness, is proud to announce its ongoing commitment to supporting and empowering girls and women in the Temecula community.

Key Points: 
  • Winona , a leading advocate for comprehensive wellness, is proud to announce its ongoing commitment to supporting and empowering girls and women in the Temecula community.
  • (Photo: Business Wire)
    As part of Winona's dedication to empowering young women, they have proudly sponsored various athletics programs at Temecula Valley High School, including Girls Water Polo, Girls Lacrosse, and the banner program.
  • By providing financial support and resources, Winona aims to encourage participation in sports and promote physical health among high school girls.
  • Dedicated to empowering girls and women through education, community engagement, and support, Winona promotes physical, mental, and emotional well-being.

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

Retrieved on: 
Thursday, May 25, 2023
TVHS, Progression-free survival, Cancer, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Associate, Stage 2, TME, Patient, Melanoma, CD40, Principal, PD-1, United States Department of Veterans Affairs, Pembrolizumab, Therapy, Safety, Pharmaceutical industry, Vaccine, Pharmacology, Medicine

“The limited efficacy of these agents is often due to ‘cold’ tumor microenvironments (TME) that prevent the infiltration of immune effector cells.

Key Points: 
  • “The limited efficacy of these agents is often due to ‘cold’ tumor microenvironments (TME) that prevent the infiltration of immune effector cells.
  • I look forward to conducting the study and to the important scientific insights I expect it will provide.”
    The investigator-sponsored Phase 2 trial is an open-label, two-stage, single arm study.
  • Stage 1 of the trial is expected to include ten patients.
  • Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.